X-linked muscular dystrophy (Duchenne/Becker) - Symptoms, Causes, Treatment & Prevention

```html

Overview

X‑linked muscular dystrophy (X‑MD) refers primarily to two related genetic disorders—Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). Both are caused by mutations in the DMD gene on the X chromosome, which encodes the protein dystrophin. Dystrophin stabilises muscle cell membranes; without enough functional protein, muscle fibers become damaged and are gradually replaced by scar tissue and fat.

Who it affects: Because the gene is located on the X chromosome, the disease predominantly affects males (who have only one X chromosome). Female carriers are usually asymptomatic but can occasionally show mild muscle weakness or cardiac involvement.

Prevalence:

• Duchenne muscular dystrophy – about 1 in 3,500–5,000 live male births worldwide (≈ 0.02 %).
• Becker muscular dystrophy – roughly 1 in 18,000–30,000 live male births.

These figures are derived from data compiled by the Muscular Dystrophy Association (MDA) and the World Health Organization (WHO) <sup>[1]</sup>.

Symptoms

Symptoms differ in age of onset and severity, but both disorders share a core set of clinical features. The table below outlines the most common manifestations:

System	Symptom	Description
Musculoskeletal	Progressive muscle weakness	Begins in the proximal (hip‑ and shoulder‑level) muscles; in DMD usually evident before age 5, in BMD during late childhood or adolescence.
Musculoskeletal	Gowers’ sign	Using hands to “climb” up the thighs to stand, indicating weakened thigh muscles.
Musculoskeletal	Waddling gait	Pelvic tilt and widened stance caused by weak hip abductors.
Musculoskeletal	Contractures	Permanent shortening of muscles/tendons, especially at the elbows, ankles, and knees.
Musculoskeletal	Lordosis & scoliosis	Spinal curvature develops as trunk muscles weaken.
Respiratory	Reduced cough strength	Leads to mucus retention and infections.
Respiratory	Progressive ventilatory decline	Often requires non‑invasive ventilation (BiPAP) in the teenage years (DMD) or later (BMD).
Cardiac	Cardiomyopathy	Dilated cardiomyopathy and arrhythmias appear in late childhood (DMD) or early adulthood (BMD).
Neurological	Learning difficulties	Seen in ~30 % of boys with DMD, often related to attention‑deficit/hyperactivity disorder (ADHD) or mild intellectual disability.
Gastrointestinal	Feeding difficulties	Weakness of oropharyngeal muscles can cause choking or poor weight gain in early childhood.
Genitourinary	Urinary incontinence	Occasional in adolescents due to pelvic floor weakness.
Skin	Subcutaneous (muscle) pseudohypertrophy	Calf enlargement from fat and connective tissue rather than true muscle growth (classic “pseudohypertrophic calves”).

Causes and Risk Factors

Genetic cause

The DMD gene is one of the largest human genes (≈ 2.2 million base pairs). Mutations can be:

• Deletions (≈ 60–70 % of cases)
• Duplication
• Point mutations or small insertions/deletions

In Duchenne muscular dystrophy the mutation eliminates or severely truncates dystrophin, yielding ≤ 3 % of normal protein. In Becker the mutation allows production of a shortened but partially functional protein (> 10 % of normal), resulting in milder disease.

Inheritance pattern

Both are inherited in an X‑linked recessive fashion:

• Carrier mothers have a 50 % chance of passing the mutated gene to each son (who will be affected) and a 50 % chance of passing it to each daughter (who becomes a carrier).
• Approximately one‑third of cases are de‑novo mutations, meaning the mother has no family history.

Who is at higher risk?

• Male infants with a known carrier mother.
• Families with a previous child diagnosed with DMD or BMD.
• Ethnic groups with higher carrier frequencies (e.g., certain European sub‑populations have slightly higher rates).

Diagnosis

Early diagnosis is essential for timely intervention. The diagnostic pathway typically includes:

1. Clinical evaluation

• Detailed history (age of onset, family pattern, developmental milestones).
• Physical exam focusing on muscle strength, gait, Gowers’ sign, and contractures.

2. Laboratory testing

• Creatine kinase (CK) level – Often >10‑20 times the upper limit of normal in DMD; moderately elevated in BMD.

3. Genetic testing

• Multiplex ligation‑dependent probe amplification (MLPA) or next‑generation sequencing (NGS) to identify deletions/duplications or point mutations.
• Carrier testing for female relatives.

4. Muscle biopsy (less common today)

When genetic testing is inconclusive, a biopsy with immunohistochemical staining for dystrophin can demonstrate reduced or absent protein.

5. Cardiac & respiratory baseline studies

• Electrocardiogram (ECG) and echocardiogram – Detect early cardiomyopathy.
• Pulmonary function tests (spirometry) – Establish baseline ventilatory capacity.

Diagnostic criteria (per NIH Consensus)

A definitive diagnosis requires either a pathogenic DMD mutation or a combination of:

• Elevated CK,
• Typical clinical picture, and
• Family history consistent with X‑linked inheritance.

Treatment Options

There is no cure, but a multidisciplinary approach can slow progression, improve quality of life, and extend survival.

1. Pharmacologic therapies

• Corticosteroids (prednisone, deflazacort) – Proven to delay loss of ambulation by 2–3 years and improve pulmonary function. Typical dose: prednisone 0.75 mg/kg/day.
• Eteplirsen (Exondys 51) – An exon‑51 skipping antisense oligonucleotide approved for DMD amenable mutations; modestly increases dystrophin production.
• Golodirsen, Viltolarsen, Casimersen – Similar exon‑skipping agents targeting other exons; indicated for specific mutation subsets.
• Cardiac medications – ACE inhibitors or ARBs (e.g., enalapril) started early to forestall cardiomyopathy; beta‑blockers when indicated.
• Respiratory drugs – Long‑term nocturnal non‑invasive ventilation (BiPAP) and cough‑assist devices.

2. Physical & occupational therapy

• Daily stretching to prevent contractures.
• Low‑impact aerobic activities (e.g., swimming, stationary cycling) to maintain muscle stamina.
• Assistive devices (orthoses, powered wheelchairs) tailored to disease stage.

3. Surgical interventions

• Orthopedic surgery for severe scoliosis or hip contractures.
• Percutaneous gastrostomy (PEG) tube placement when swallowing becomes unsafe.

4. Emerging therapies (clinical trial landscape)

• Gene therapy – Micro‑dystrophin AAV vectors are in Phase III trials; early data show stable expression and functional benefit.
• CRISPR‑based editing – Pre‑clinical models demonstrate restored dystrophin, but human trials are pending.
• Utrophin up‑regulators – Small molecules (e.g., ezutromid) aim to increase the compensatory protein utrophin.

5. Psychosocial support

Psychological counseling, educational accommodations, and support groups (e.g., Parent Project Muscular Dystrophy) are vital for patients and families.

Living with X‑linked Muscular Dystrophy (Duchenne/Becker)

Managing day‑to‑day life involves a blend of medical care, home adaptations, and lifestyle choices.

Practical tips

• Routine monitoring – Cardiology check‑up every 12 months (earlier if symptoms appear); pulmonary function every 6‑12 months.
• Stretching program – 10–15 minutes each major muscle group twice daily; incorporate night‑time splints if prescribed.
• Nutrition – High‑protein, calorie‑dense diet to counteract increased metabolic demands; consider supplementation with vitamin D and calcium for bone health.
• Energy conservation – Plan activities when energy levels are highest (usually mornings); use adaptive equipment such as reachers, shower chairs, and powered scooters.
• School & work accommodations – Request Individualized Education Programs (IEPs) or Workplace Adjustments; allow extra time for tasks and frequent breaks.
• Vaccinations – Annual influenza vaccine and pneumococcal vaccination are especially important given respiratory vulnerability.
• Family planning for carriers – Genetic counseling, prenatal testing, or pre‑implantation genetic diagnosis (PGD) are options for women who carry a DMD mutation.

Support resources

• Muscular Dystrophy Association (MDA) – mda.org
• Parent Project Muscular Dystrophy – parentprojectmd.org
• National Organization for Rare Disorders (NORD) – rarediseases.org

Prevention

Because X‑linked muscular dystrophy is genetic, true primary prevention is not possible. However, risk can be reduced through:

• Carrier screening – Women with a family history should undergo genetic testing before pregnancy.
• Prenatal diagnostic options – Chorionic villus sampling (CVS) or amniocentesis can detect DMD mutations early.
• Pre‑implantation genetic diagnosis (PGD) – Allows selection of embryos without the mutation during in‑vitro fertilisation.

These measures do not affect the health of an already‑born child but enable informed reproductive decisions.

Complications

If left unmanaged, X‑linked muscular dystrophy can lead to serious, life‑threatening issues:

• Respiratory failure – Progressive weakness of diaphragm and intercostal muscles; leading cause of death in DMD (median survival into the 30s).
• Cardiomyopathy & arrhythmias – Dilated cardiomyopathy may progress to heart failure; sudden cardiac death can occur.
• Severe scoliosis – Impairs pulmonary mechanics and may require surgical correction.
• Joint contractures – Limit mobility and affect positioning, increasing pressure‑ulcer risk.
• Bone health decline – Steroid use and reduced weight‑bearing raise osteoporosis risk; fractures are common.
• Psychosocial impact – Depression, anxiety, and social isolation are reported in up to 40 % of adolescents.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Duchenne muscular dystrophy. https://www.mayoclinic.org
2. Centers for Disease Control and Prevention. Muscular Dystrophy Fact Sheet. https://www.cdc.gov
3. NIH National Institute of Neurological Disorders and Stroke. Becker Muscular Dystrophy Information Page. https://www.ninds.nih.gov
4. Cleveland Clinic. Duchenne muscular dystrophy: Treatment & Management. https://my.clevelandclinic.org
5. World Health Organization. Neuromuscular Disorders: Overview. https://www.who.int
6. Parent Project Muscular Dystrophy. Clinical Trials & Research. https://www.parentprojectmd.org

```